1-8 of 8
Lia E Perez
Close
Sort by
Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

Clinical Trials & Observations
Joseph A Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia E Perez, Rawan G Faramand, Marco L. Davila, Shannon McSain, Jordan Pleskow, Jeffrey Baron, Claudio Anasetti, Carlos M Moran Segura, Daniel J Weisdorf, Bruce R Blazar, Jeffrey S. Miller, Veronika Bachanova, Najla El Jurdi, Brian C Betts
Journal: Blood
Blood blood.2024024789.
https://doi.org/10.1182/blood.2024024789
Published: 2024
Includes: Supplemental data
Journal Articles

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Ariosto Silva, PhD, Maria Silva, M.Sc, Timothy Jacobson, B.S., Mark B Meads, PhD, Allison Distler, B.S., Aunshka Collins, BS, Chris Cubitt, PhD, Lia E Perez, MD, Rachid Baz, MD, Dmitri Rebatchouk, PhD, Robert Gatenby, MD, PhD, Kenneth H. Shain, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3291.
https://doi.org/10.1182/blood.V128.22.3291.3291
Published: 2016
Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS
Journal: Blood
Blood (2011) 118 (21): 3022.
https://doi.org/10.1182/blood.V118.21.3022.3022
Published: 2011
Journal Articles

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Marina Molisano, BS, Ken Shain, Ph.D, Melisa Alsina, MD, Claudio Anasetti, MD, William Dalton, Ph.D. MD
Journal: Blood
Blood (2007) 110 (11): 3521.
https://doi.org/10.1182/blood.V110.11.3521.3521
Published: 2007
Journal Articles

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Ramadevi Nimmanapalli, DVM, PhD, Melissa Alsina, M.D, Claudio Anasetti, MD, William Dalton, PhD MD
Journal: Blood
Blood (2005) 106 (11): 2489.
https://doi.org/10.1182/blood.V106.11.2489.2489
Published: 2005
Journal Articles

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Nancy Parquet, B.S., Ramadevi Nimmanapalli, D.V.M. Ph.D., Claudio Anasetti, M.D., Melissa Alsina, M.D., William Dalton, Ph.D. M.D., Lia E. Perez, M.D.
Journal: Blood
Blood (2004) 104 (11): 2459.
https://doi.org/10.1182/blood.V104.11.2459.2459
Published: 2004
Journal Articles

SH2-Containing-5′Inositol Phosphatase-1 (SHIP) Regulates Megakaryocytic Progenitors Numbers (MKP) and Determines Megakaryocyte (MK) In Vivo Localization.

Lia E. Perez, M.D., Caroline Desponts, B.S., Nancy Parquet, B.S., William G. Kerr, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2780.
https://doi.org/10.1182/blood.V104.11.2780.2780
Published: 2004
Journal Articles

Xenotransplantation of immunodeficient mice with mobilized human blood CD34 + cells provides an in vivo model for human megakaryocytopoiesis and platelet production

Lia E. Perez, Henry M. Rinder, Chao Wang, Jayne B. Tracey, Noel Maun, Diane S. Krause
Journal: Blood
Blood (2001) 97 (6): 1635–1643.
https://doi.org/10.1182/blood.V97.6.1635
Published: 2001